Immediate versus delayed surgery for hip fractures in the elderly patients: a protocol for a systematic review and meta-analysis

Abstract

Background

Hip fractures are a major public health problem in elderly populations and are accompanied by high-mortality rates. Whether timing of surgery has an impact on morbidity and mortality has been discussed controversially, numerous studies suggest that the delay of surgery can significantly increase the risk of morbidity and mortality; others report that achieving a stable medical condition is more important than early surgery. The goal of our systematic review is to assess the impact of timing of surgery on health outcomes in patients aged 60 years or older with acute hip fracture. In addition, we will investigate differences in beneficial or harmful effects of timing of surgery in subgroups of patients based on demographic characteristics, physical status, and the use of anticoagulant medications.

Methods

We will systematically search MEDLINE via Ovid, the Cochrane Library, Embase, PubMed, and clinical trial registries (from 1997 to 2017). In addition, we will search reference lists of pertinent reviews, archives of annual meetings of orthopaedic societies, and contact experts. We will include randomized controlled trials and non-randomized studies assessing the impact of timing of surgery after hip fracture in patients 60 years or older, published in English or German. Our outcomes of interest include health outcomes such as mortality, perioperative complications, functional capacity, and quality of life. We plan to perform meta-analyses if we have at least three sufficiently similar studies. If data are sufficient, we will conduct subgroup-analyses testing for differences between age groups, sex, patients’ physical status as assessed with ASA (American Society of Anesthesiologists) scores, and the use of anticoagulation.

Discussion

Since this is the first systematic review on this topic since 2010, our findings will help to inform clinical practice guidelines concerning timing of surgery in hip fractures. Furthermore, our findings could contribute to define an optimal time period for surgery for different groups of patients with acute hip fracture.

Systematic review registration

PROSPERO 2017 CRD42017058216

Electronic supplementary material

The online version of this article (doi:10.1186/s13643-017-0559-7) contains supplementary material, which is available to authorized users.

Background

Hip fractures are a major public health problem in elderly populations in Europe and the USA [1, 2]. In the USA, the reported incidence of hip fractures in elderly citizens is 1.1% per year [3, 4]. In Europe, the incidence ranges between 0.5 and 1.6% per year in elderly women [5–7] and about half of that risk in men [4].

Hip fractures in elderly patients are serious injuries that can lead to death, immobility, and permanent dependence, resulting in a high financial burden for health systems and societies [4, 7–9]. In senior patients, mortality rates following hip fractures range between 14 and 36% within 1 year of the injury [10–18]. Considering that life expectancy in Western countries will increase over the next decades [19–21], the burden of disease of hip fractures and their consequences will develop into an even greater public health issue in the near future.

The prognosis of elderly patients with acute hip fractures depends primarily on age, comorbidities, anticoagulation therapy, and the general physical health status [22]. In addition, mounting evidence indicates that timing of surgery might play a major role in survival after hip fracture [23–29]. Studies suggest that a delay of surgery can significantly increase the risk of morbidity and mortality in elderly patients [23–26, 30–32]. In 2010, a systematic review reported that early surgery (within 24–72 h) can reduce the risk of mortality in elderly patients by 19% [33]. These results corroborated findings of previous reviews showing that a delay of surgery beyond 48 h increased mortality within 1 year by 32% [26]. Furthermore, delayed surgery increased the risk of pneumonia [27].

Although many evidence-based guidelines recommend surgery of acute hip fracture within 48 h [34, 35], such recommendations are still controversial. Some researchers argue that delayed surgery provides valuable time for patients to achieve a better medical condition before surgery, which reduces the risk of perioperative complications, including pneumonia, deep venous thrombosis, bleeding, pulmonary embolism, urinary tract infections, and decubital ulcerations [28, 29, 36]. In clinical practice, delayed surgery of hip fractures is quite common because of a limited capacity of operating rooms or personnel, or the need for medical stabilization or anticoagulation reversal of patients before surgery [33].

The objective of our review is to systematically and objectively summarize the evidence on the impact of timing of surgery on patient-relevant health outcomes in elderly patients with acute hip fracture. In doing so, we will address several limitations of a well-conducted review by Simunovic et al. that focused on mortality [33]. In our review, we strive to address several clinically relevant questions and outcomes that were not addressed fully by the Simunovic et al. review. First, in addition to mortality, we will also focus on other patient-relevant outcomes, such as perioperative complications, functional capacity, or quality of life and aim to include studies reporting any of these outcomes. Second, if data allow, we will explore differences in benefits and harms in clinically relevant subgroups such as patients on anticoagulation treatment or patients with different American Society of Anesthesiologists (ASA) physical status classifications. Third, in addition to randomized controlled trials (RCTs), we will also include prospective controlled non-randomized studies. Non-randomized studies often provide better evidence on rare but potentially harmful events than RCTs.

Methods

Research questions and analytic framework

Our systematic review will address the following key questions (KQ), which are also illustrated in an analytical framework (Fig. 1).

Fig. 1.

Analytic framework

KQ 1: In patients aged 60 years or older with acute hip fracture, what is the impact of timing of the surgery on beneficial and harmful outcomes such as mortality, functional capacity, quality of life, or perioperative complications?

KQ 2: Do beneficial or harmful treatment effects of timing of the surgery vary by subgroups based on patient characteristics (age, sex), physical status (e.g., ASA Physical Status System), or common medical treatments (e.g., anticoagulation treatment)?

Protocol and registration

We have registered our systematic review with the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42017058216. Throughout the protocol, we followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)-Protocols statement [37] (see Additional file 1).

Eligibility criteria

Our population of interest are patients 60 years or older with acute hip fracture (intra- and extracapsular) who undergo surgical repair of the fracture. We will include randomized and non-randomized controlled trials (RCTs and nRCTs, respectively), and prospective controlled observational studies comparing early versus delayed surgery after acute hip fracture. Our outcomes of interest include health outcomes such as mortality, perioperative complications, functional capacity, and quality of life. Table 1 presents the inclusion and exclusion criteria.

Table 1.

Inclusion and exclusion criteria

Category	Criteria
	Inclusion	Exclusion
Population	• Adult (60 years or older) patients undergoing surgery for acute intra- or extracapsular hip fracture	• Adults under the age of 60 years • Patients undergoing surgery for reasons other than intra- or extracapsular hip fractures • Patients with hip fractures not related to an acute trauma • Patients with pathological fractures • Patients with periprosthetic fractures
Geography	• No limitation	• No limitation
Date of search	• Searches will go back to 1997
Interventions	• Early surgery for hip fracture. We will use the definition for “early” as defined by authors in the primary study.	• We will exclude studies that do not compare timing of surgery
Control interventions	• Delayed surgery for hip fracture. We will include all categories of “delayed” as defined by authors in the primary study.	• We will exclude studies that do not compare timing of surgery
Outcomes	• All-cause mortality - Short term: at 1 month - Medium term: at 6 months - Long term: at 12 months • Severe perioperative complications - Pulmonary embolism - Pneumonia - Deep vein thrombosis - Others • Other perioperative complications - Urinary tract infection - Pressure ulcer - Others • Functional capacity • Quality of life (e.g., assessed with SF36)	• Studies that do not include at least one of the outcomes listed under the inclusion criteria
Publication language	• English, German	• All other languages
Study design	• Original research • Eligible study designs include: - RCTs - Prospective controlled cohort studies	• Case series • Case reports • Retrospective controlled cohort studies • Case-control studies • Studies without a control group
Publication type	Any publication reporting primary data	• Publications not reporting primary data • Publications available as abstract only

Data source and search strategy

We will search MEDLINE (Ovid), the Cochrane Library, Embase, and PubMed (non-MEDLINE content) as well as the following trials registries: World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov. We will limit our searches to English and German language literature, which reflects the language capabilities of our team. We will restrict the search to studies published since 1997. In addition to database searches, we will check reference lists of included articles and contact experts. An information specialist developed a comprehensive MEDLINE search strategy (see Additional file 2). The search strategy is based on a set of included studies of an existing systematic review [33] and was tested with a set of included studies of another review on this topic.

We will also handsearch the archives of annual meetings of the Orthopaedic Trauma Association, the International Society of Orthopaedic Surgery and Traumatology, the Canadian Orthopaedic Association, the European Federation of National Associations of Orthopaedics and Traumatology, the Mid-America Orthopaedic Association, the Piedmont Orthopedic Society, the Association of Bone and Joint Surgeons, the American Academy of Orthopaedic Surgeons, the Austrian Trauma Society, the Austrian Society for Orthopaedics and Orthopaedic Surgery, the German Society for Orthopaedics and Trauma, the German Society for Orthopaedics, and Orthopaedic Surgery and the German Trauma Society (all 2008–2017).

In case information about relevant outcomes or study characteristics is missing, we will contact authors of the studies and request additional information.

Study selection

After piloting the study selection process, abstracts and full-text articles will be reviewed in two consecutive steps, by two review authors independently. Disagreements will be resolved by consensus or in consultation with a third author. We will use the software Covidence [38] to facilitate abstract/full-text selection and present the results of the study selection process using the PRISMA flowchart. We will include all records that meet our a priori defined selection criteria (see Table 1).

Data extraction and risk of bias assessment

We will design and pilot a structured data abstraction form. Two review authors will independently extract the following information on all included studies: authors’ name, title, year of publication, study design, country, characteristics of study population (age, sex, patients’ fitness for surgery with ASA score, anticoagulant medication), sample size, type of hip fracture, timing of surgery in control and intervention group, adjustment for potential confounding, effect sizes of predefined outcomes with 95% confidence interval (CI), and counts of events for dichotomous outcomes.

Two review authors will independently assess the quality of the included studies using Cochrane Risk of Bias tool for randomized controlled trials [39] and the Newcastle Ottawa tool [40]. Disagreements will be resolved by consensus, or if necessary, in consultation with a third review author.

Assessing the quality of the evidence

In addition, the quality of evidence will be assessed for relevant endpoints using the approach of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group [41]. Where good-quality studies are available, the evidence will be considered to be associated with a low risk of bias. Evidence will be assessed as being consistent if the effect sizes are similar across the individual studies and pointed in the same direction. Evidence will be classed as direct when it demonstrates a direct relationship between the intervention and the health-relevant endpoint and the results of the study are applicable to the target population. It will be classed as precise when the results show a low degree of uncertainty. Finally, the quality of evidence will be classed as high, moderate, low, or very low. If the quality is high, the authors are very confident that the true effect is close to the effect estimate. In contrast, if the quality is very low, the authors assume that the true effect is likely to be significantly different from the effect estimate [42].

Outcomes of interest

We will employ the GRADE approach to prioritize outcomes that are relevant for decision-making and for patients. Clinical experts will rate the relative importance of outcomes on a Likert scale from 1 (not relevant) to 9 (critical) via a Web-based survey using a modified Delphi approach. According to the generated mean values, we will prioritize outcomes of interest.

Data synthesis and statistical analysis

We will consider performing meta-analyses where we have at least three unique studies of low or medium risk of bias that we deem to be sufficiently similar (in population, interventions, comparators, and outcomes). We plan to combine only studies using similar cutoffs for “early” and “delayed” surgery in a meta-analysis. Because cut-offs will vary across studies due to differences in clinical practice between centres and countries/regions, we will ask experts via a modified Delphi approach what time frames are still similar enough to be combined in a meta-analysis. We are aware of the potential biases of meta-analyses that include a small number of studies; before calculating a pooled summary estimate in a meta-analysis, we will carefully consider the heterogeneity across studies. Therefore, bodies of evidence containing fewer than three low or medium risk of bias studies or with heterogeneous or noncomparable study populations will only be used in qualitative syntheses.

For meta-analysis of trials, we will use a random-effects model. We plan to exclude studies deemed high risk of bias from our main analyses; we will include them only in sensitivity analyses. For meta-analyses of non-randomized studies, we will use generic inverse variance models to combine effects of individual studies that are adjusted for potential confounders. We will include unadjusted results only in sensitivity analyses.

To assess statistical heterogeneity in effects between studies, we will calculate the chi-squared statistic and the I ² statistic (the proportion of variation in study estimates attributable to heterogeneity rather than due to chance [43, 44]. An I ² from 0 to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% or greater represents considerable heterogeneity [39]. For the chi-squared statistic, we will adopt a p value of 0.1 as a threshold for clinical significance. In cases of high heterogeneity, we will explore potential reasons for heterogeneity. If we encounter high unexplained heterogeneity, we will abstain from any quantitative syntheses.

To assess publication bias, we will use funnel plots and Kendall’s tests, being aware that these tests have low sensitivity to detect publication bias, particularly with a small number of studies.

If data are sufficient, we will conduct subgroup-analyses testing for differences between age groups (60–75 years, 75.1–85 years, 85.1 years, or older), sex, patients’ physical status assessed with ASA scores, and anticoagulation.

Discussion

Our protocol presents the methodological approach of a systematic review that will assess the effect of timing of surgery in elderly patients with acute hip fractures. In addition, the review will focus on differences of the impact of timing of surgery in subgroups such as patients on anticoagulation medication or patients with different ASA physical statuses. To our knowledge, our review will be the first study that systematically summarizes the literature on these clinically relevant questions in almost a decade.

Delays in surgeries after acute hip fracture in elderly patients are common and attributable to several factors. For example, differences between national healthcare systems and infrastructures of hospitals can influence timing of surgical interventions [30]. Specifically, in hospitals with several surgical disciplines, a competition for limited acute surgical capacities (e.g., operating rooms) may determine the timing of surgery. A comprehensive up-to-date evidence synthesis could provide the basis to prioritise early hip surgery.

Another factor contributing to delayed surgery is anticoagulant medications, particularly new oral anticoagulants (NOACs). Many patients suffering from hip fractures are treated with anticoagulant medication [45–47]. For some NOACs, no specific antidotes to block their activity are currently available [48–50]. Doctors, therefore, often prefer to wait for the effects of this medication to wear off prior to operating on the patient. Such an approach, however, is controversial because studies have claimed that patients treated with NOACs survive early surgery without any adverse health effects [51, 52]. We hope that our review will provide better insight into this clinically important matter.

Finally, various routines for assessing a patient’s health status have emerged [53, 54]. Some authors argue that patients with a poor health status must be medically stabilized before any surgery can be performed to avoid harm as a consequence of the surgical intervention [55]. To date, it remains unclear if delayed surgery is beneficial for patients with a poor physical status.

Overall, we are confident that a comprehensive summary of the best available evidence on timing of surgery for elderly patients with hip fractures will have an impact on clinical practice guidelines and will ultimately improve patient care.

Abbreviations

ASA

American Society of Anesthesiologists

CI

Confidence interval

e.g.

For example

GRADE

Grading of Recommendations Assessment, Development and Evaluation

ICTRP

International Clinical Trials Registry Platform

KQ

Key questions

NOACs

New oral anticoagulants

nRCT

Non-randomized controlled trial

PRISMA

Preferred Reporting Items for Systematic Review and Meta-Analysis

PROSPERO

International Prospective Register of Systematic Reviews

RCT

Randomized controlled trial

WHO

World Health Organization

Authors’ contributions

All authors made substantial contribution to the conception and design of this protocol. As an information specialist, IK developed the search strategy. TK, CS, CR, and BNS have drafted the manuscript. BW, GW, GG, SN, and ML revised it critically. All authors have given approval of this version to be published.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

Without any relevance to this work, Thomas Klestil has received travel grants from DePuy. Christoph Röder has received workshop compensation and travel grants from DePuy and Arthrex. Christoph Stotter has received workshop compensation and travel grants from DePuy. Birgit Winkler has received travel grants from DePuy and Arthrex. Stefan Nehrer has received travel grants, speaker’s fee and workshop compensation from DePuy, Otto Bock Austria GmbH, Braincon Handels-GmbH, Arthrex, Haemo Pharma GmbH, and Co.don AG. Martin Lutz, Irma Klerings, Gernot Wagner, Gerald Gartlehner, Barbara Nussbaumer-Streit declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.